Oral health in oncology: impact of immunotherapy – Online First – Springer

The overall survival benefit seen with ipilimumab, an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and T cell checkpoint inhibitor, has ushered in a new and exciting era for treatment of metastatic melanoma [1]. Newer antibodies targeting other immune checkpoints like programmed cell death-1 and its ligand (PD-1/PD-L1) have also induced durable tumor regression and stabilization of disease in melanoma, renal cell carcinoma, and non-small cell lung cancer [2]. These and other immune-based therapies are expected to play a significant role in these and other cancers in the future.

via Oral health in oncology: impact of immunotherapy – Online First – Springer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s